Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | PYGB | P11216 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28448523 | 1.00 | CA12 (0.44) | CA12CA1CA2CA9PYGB | |
| SCHEMBL28448246 | 1.00 | CA12 (0.44) | CA12CA1CA2CA9PYGB | |
| SCHEMBL28444663 | 1.00 | CA12 (0.44) | CA12CA1CA2CA9PYGB | |
| SCHEMBL9346601 | 0.99 | CA12 (0.42) | CA12CA1CA2CA9PYGB | |
| SCHEMBL2723573 | 0.87 | PYGB (0.43) | CA12CA1CA2CA9PYGB | |
| SCHEMBL30259669 | 0.84 | FOLH1 (0.40) | CA12CA1CA2CA9FOLH1 | |
| SCHEMBL29240455 | 0.84 | FOLH1 (0.40) | CA12CA1CA2CA9FOLH1 | |
| SCHEMBL31150424 | 0.83 | CA12 (0.43) | CA12CA1CA2CA9PYGB | |
| SCHEMBL29439292 | 0.83 | CA12 (0.43) | CA12CA1CA2CA9PYGB | |
| SCHEMBL20265935 | 0.83 | CA12 (0.43) | CA12CA1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304631-B1 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | UNIV GENT (BE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240216480-A1 | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE | UNIV GENT (BE) | 2024-07-04 | — | — | US | disclosed |
| US-8138227-B2 | Method for inhibiting or reversing non-enzymatic glycation | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080009547-A1 | Method for inhibiting or reversing non-enzymatic glycation | TRUSTEES OF DARTMOUTH COLLEGE | 2008-01-10 | — | — | US | disclosed |
| WO-1992005796-A1 | PEPTIDE INHIBITORS OF NEUTROPHIL ACTIVATION PROTEINS | SRI INTERNATIONAL (US) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009547-A1 | Method for inhibiting or reversing non-enzymatic glycation | AGER, GLO1, GLA | CA12 2439/4885CA1 1625/4885CA2 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.